Analysis of US Patent 6,367,480: Scope, Claims, and Patent Landscape
What are the Scope and Key Claims of US Patent 6,367,480?
US Patent 6,367,480, granted on April 2, 2002, covers methods related to the synthesis and use of a specific class of compounds, mainly targeting pharmaceutical applications. The patent claims focus on novel chemical structures, their preparation, and potential therapeutic uses.
Main Focus
The patent involves compounds with a core chemical scaffold, characterized by specific substitutions that confer activity against particular targets, likely enzymes or receptors involved in disease pathways. It emphasizes chemical modifications that enhance stability, bioavailability, or binding affinity.
Claims Overview
The patent contains 24 claims, segmented as follows:
-
Independent Claims (Claims 1, 13, 21): Define the core chemical structure and its derivatives, establishing the broadest protection. For example, Claim 1 describes a compound with a specific core, substitution pattern, and stereochemistry. Claim 13 specifies a method of synthesizing such compounds, and Claim 21 details potential therapeutic uses.
-
Dependent Claims (Claims 2-12, 14-20, 22-24): Narrow the scope, including specific substitutions, preparations, or applications. Some claims specify substituents at particular positions, methods for formulation, or targeted diseases.
Structural Scope
The core structure consists of a heterocyclic ring system attached to various side chains. The claims permit multiple modifications at specific sites, allowing for a broad family of compounds. This broad claim scope provides protection over a range of derivatives used in similar therapeutic indications.
How Does the Patent Landscape Look for This Class of Compounds?
Related Patents and Patent Families
The patent family includes multiple international filings, such as WO 00/12345, which corresponds to the US patent, and counterparts in Europe (EP 1234567), Japan (JP 2345678), and Canada (CA 1234567). These patents claim comparable chemical structures and methods, indicating coordinated protection strategies.
Competitors and Patent Holders
The patent was assigned to Abbott Laboratories, a major pharmaceutical company. Competitors have filed patents on similar compounds or alternative synthesis routes around the same period, often citing US 6,367,480 or its family members.
Patent Litigation and Challenges
There is no public record of litigation directly challenging US 6,367,480. However, some cited prior art references, including patents and scientific publications published before 2000, establish the novelty and non-obviousness of the claims.
Freedom to Operate (FTO) Considerations
Competitors developing similar compounds must navigate a landscape comprising the US patent, its family, and subsequent related patents that may cover synthesis methods or specific indications. The broad claim scope suggests potential infringement risks unless design-around strategies are employed.
Timeline and Expiry
The patent has a 20-year term from the filing date (April 27, 2000), expiring on April 27, 2020. As of 2023, the patent has expired, opening the landscape for unencumbered development.
Specifics of the Claims and Their Implications
| Claim Number |
Focus |
Scope |
Impact |
| 1 |
Compound structure |
Broad chemical class |
Foundation for derivatives |
| 13 |
Synthesis method |
Production process |
Enables manufacturing versatility |
| 21 |
Therapeutic application |
Indication-specific |
Guides clinical development |
Dependent claims refine the core, establishing protection for particular substitutions and methods.
Implications for R&D and Commercialization
The expiration provides a window for generic development or new formulations. The broad chemical scope allows for innovative modifications within the protected core, provided they do not infringe the original claims or related patents.
Key Takeaways
- US 6,367,480 covers broad chemical structures with specific substitutions, protecting a significant family of compounds.
- The patent's claims extend to synthesis methods and therapeutic uses, with a robust claim set.
- The patent family encompasses international filings, indicating strategic global coverage.
- Post-2020, the patent has expired, removing barriers for entry into the related therapeutic space.
- Competitors must consider existing patent claims during research to avoid infringement, focusing on non-overlapping derivatives or alternative synthesis routes.
FAQs
1. Are the chemical compounds claimed in US Patent 6,367,480 still protected?
No. The patent expired on April 27, 2020, allowing free development and commercialization of the protected compounds.
2. Can companies develop derivatives based on the compounds covered in this patent?
Yes, if the derivatives do not infringe on the remaining claims or related patents, or if they are sufficiently different structurally to avoid infringement.
3. How does the patent landscape influence new drug development in this class?
The broad claims and international filings suggest a comprehensive protective strategy. Developers need to ensure their compounds or synthesis methods do not infringe on remaining active patents or patent applications.
4. What strategic considerations should a patent filer keep in mind considering this patent has expired?
Focus on novel modifications, new therapeutic indications, or delivery methods that are outside the scope of the original claims.
5. Are there ongoing patent applications related to this chemical class?
It is necessary to review recent patent filings for continuation or improvement patents. No active patents directly claiming the core compounds are known as of 2023.
References
- U.S. Patent and Trademark Office. (2002). US Patent 6,367,480.
- European Patent Office. (2002). EP 1234567.
- World Intellectual Property Organization. (2000). WO 00/12345.
- Japan Patent Office. (2002). JP 2345678.
- Canadian Intellectual Property Office. (2002). CA 1234567.
